Патогенетическое обоснование выбора антитромботических препаратов больным с острым коронарным синдромом в сочетании с дисфункцией почек

Авторы: М.В. Зыков

Организация:
ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»; Сосновый б-р, 6, г. Кемерово, 650002, Российская Федерация;

МБУЗ «Городская больница № 4»; ул. Туапсинская, 1, Сочи, 354057, Российская Федерация

Для корреспонденции: Сведения доступны для зарегистрированных пользователей.

Раздел: Острый инфаркт миокарда

Библиографическая ссылка: Креативная кардиология. 2016; 10 (1): 5-12

Цитировать как: М.В. Зыков. Патогенетическое обоснование выбора антитромботических препаратов больным с острым коронарным синдромом в сочетании с дисфункцией почек. Креативная кардиология. 2016; 10 (1): 5-12. DOI:

Ключевые слова: острый коронарный синдром, дисфункция почек, антитромботическая терапия

Полнотекстовая версия:  

Аннотация

Цель настоящего обзора – помочь врачу совместно с имеющимися официальными рекомендациями более аргументированно назначать антитромботическую терапию больным с острым коронарным синдромом в сочетании с нарушением функции почек. В обзоре приведены современные данные об особенностях действия применяемых при остром коронарном синдроме антиагрегантов и антикоагулянтов в условиях почечной дисфункции.

Литература

1. Fox C.S., Muntner P., Chen A.Y., Alexander K.P., RoeM.T., Cannon C.P. et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-seg- ment elevation myocardial infarction in patients with chronic kidney disease: a report from the national cardiovascular data acute coronary treat­ment and intervention outcomes network registry. Circulation. 2010; 121 (3): 357—5.

2. Baber U., Stone G.W., Weisz G., Moreno P., Dan- gas G., Maehara A. et al. Coronary plaque composi­tion, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc. Imaging. 2012; 5 (3): S53-61.

3. Washam J.B., Herzog C.A., Beitelshees A.L., Cohen M.G., Henry T.D., Kapur N.K. et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syn­drome: a scientific statement from the American Heart Association. Circulation. 2015; 131 (12): 1123-49.

4. Муравлева Л.Е., Молотов-Лучанский В.Б., Клю­ев Д.А. Гемостаз при хронической болезни по­чек. Мини-обзор. Современные проблемы науки и образования. 2010; 4: 36-42 / Muravleva L.E., Molotov-Luchanskiy V.B., Klyuev D.A. Hemostasis in chronic kidney disease. Mini review. Sovremen- nye problemy nauki i obrazovaniya. 2010; 4: 36-42 (in Russian).

5. Capodanno D., Angiolillo D.J. Antithrombotic thera­py in patients with chronic kidney disease. Circulation. 2012; 125: 2649-61.

6. Gremmel T., Mhller M., Steiner S., Seidinger D., Koppensteiner R., Kopp C.W. et al. Chronic kidney disease is associated with increased platelet activa­tion and poor response to antiplatelet therapy. Nephrol. Dial. Transplant. 2013; 28 (8): 2116-22.

7. Angiolillo D.J., Bernardo E., Capodanno D., Vivas D., Sabate M., Ferreiro J.L. et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J. Am. Coll. Cardiol. 2010; 55 (11): 1139-46.

8. Htun P., Fateh-Moghadam S., Bischofs C., Banya W., Mhller K., Bigalke B. et al. Low respon­siveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J. Am. Soc. Nephrol. 2011; 22 (4): 627-33.

9. Best P.J., Steinhubl S.R., Berger P.B., Dasgupta A., Brennan D.M., Sz.cz.ech L.A. et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am. Heart J. 2008; 155 (4): 687-93.

10. Dasgupta A., Steinhubl S.R., Bhatt D.L., Berger P.B., Shao M., Mak K.H. et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high athero- thrombotic risk and ischemic stabilization, manage­ment, and avoidance [CHARISMA] trial). Am. J. Cardiol. 2009; 103 (10): 1359-63.

11. Keltai M., Tonelli M., Mann J.F., Sitkei E., Lewis B.S., Hawken S. et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14 (2): 312-8.

12. Mangiacapra F., Cavallari I., Barbato E., Rico- ttini E., Patti G., Vizzi V. et al. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am. J. Cardiol. 2014; 113 (7): 1124-29.

13. Morel O., El Ghannudi S., Jesel L., Radulescu B., Meyer N., Wiesel M.L. et al. Cardiovascular mortal­ity in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly relat­ed to impaired P2Y12 inhibition by clopidogrel. J. Am. Coll. Cardiol. 2011; 57 (4): 399-408.

14. Morel O., Muller C., Jesel L., Moulin B., Hanne- douche T. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mecha­nisms, clinical relevance and pharmacological options. Nephrol. Dial. Transplant. 2013; 28: 1994-2002.

15. Dreisbach A.W. The influence of chronic renal fail­ure on drug metabolism and transport. Clin. Pharmacol. Ther. 2009; 86: 553-6.

16. Gugliucci A., Kinugasa E, Kotani K., Caccavello R., Kimura S. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin. Chem. Lab. Med. 2011; 49: 61-7.

17. Lisowska-Myjak B. Uremic toxins and their effects on multiple organ systems. Nephron Clin. Pract. 2014; 128: 303-11.

18. Chang H., Yanachkov I.B., Michelson A.D., Li Y., Barnard M.R., Wright G.E. et al. Agonist and antag­onist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb. Res. 2010; 125: 159-65.

19. Small D.S., Wrishko R.E., Ernest C.S., Ni L., Winters K.J., Farid N.A. et al. Prasugrel pharma­cokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal dis­ease. J. Clin. Pharm. Ther. 2009; 34 (5): 585-94.

20. Palmer S.C., Di Micco L., Razavian M., Craig J.C., Perkovic V., Pellegrini F. et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst. Rev. 2013; 2: CD008834.

21. Liang J., Wang Z., Shi D., Liu Y., Zhao Y., Han H. et al. High clopidogrel dose in patients with chron­ic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology. 2015; 66 (4): 319-25.

22. Park S.H., Kim W, Park C.S., Kang W.Y., Hwang S.H., Kim W. et al. A comparison of clopi- dogrel responsiveness in patients with versus with­out chronic renal failure. Am. J. Cardiol. 2009; 104 (9): 1292-5.

23. Woo J.S., Kim W, Lee S.R., Jung K.H, Kim W.S., Lew J.H. et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilosta- zol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibi­tion according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) random­ized study. Am. Heart J. 2011; 162 (6): 1018-25.

24. Siddiqi O.K., Smoot K.J., Dufour A.B., Cho K., Young M., Gagnon D.R. et al. Outcomes with pro­longed clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015; 101 (19): 1569-76.

25. James S., Budaj A., Aylward P., Buck K.K., Cannon C.P., Cornel J.H. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010; 122 (11): 1056-67.

26. Highlights of prescribing information «Ticagrelor».

Available at: http://www.accessdata.fda.gov/

drugsatfda_docs/label/2015/022433s017lbl.pdf (accessed 28 September 2015).

27. Trenk D., Stone G.W., Gawaz M., Kastrati A., Angiolillo D.J., Mhller U. et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective per­cutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER- PCI (testing platelet reactivity in patients undergo­ing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J. Am. Coll. Cardiol. 2012; 59 (24): 2159-64.

28. Wiviott S.D., Braunwald E, McCabe C.H.,

Montalescot G., Ruzyllo W, Gottlieb S. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007; 357 (20): 2001-15.

29. Wiviott S.D., Braunwald E, McCabe C.H.,

Horvath I., Keltai M., Herrman J.P. et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percuta­neous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a ran­domised trial. Lancet. 2008; 371 (9621): 1353-63.

30. Alexopoulos D., Panagiotou A., Xanthopoulou I., Komninakis D., Kassimis G., Davlouros P. et al.

Antiplatelet effects of prasugrel vs. double clopido- grel in patients on hemodialysis and with high on- treatment platelet reactivity. J. Thromb. Haemost. 2011; 9 (12): 2379-85.

31. Roffi M., Patrono C., Collet J.P., Mueller C., Valgimigli M., Andreotti F.et al. 2015 ESC guide­lines for the management of acute coronary syn­dromes in patients presenting without persistent ST-segment elevation. Task force for the manage­ment of acute coronary syndromes in patients pre­senting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016; 37: 267-315.

32. Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., Falk V. et al. 2014 ESC/EACTS Guide­lines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2014; 35: 2541-619.

33. Camm A.J., Lip G.Y.H., De Caterina R., Savelieva I., Atar D., Hohnloser S.H. et al. 2012 focused update of the ESC Guidelines for the management of atri­al fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012; 33: 2719-47.

34. Bohm M., Ezekowitz M.D., Connolly S.J., Eikel- boom J.W., Hohnloser S.H., Reilly P.A. et al. Changes in renal function in patients with atrial fib­rillation: an analysis from the RE-LY trial. J. Am. Coll. Cardiol. 2015; 65 (23): 2481-93.

35. Asinger R.W., Shroff G.R. Atrial fibrillation and renal function. How high is the price of anticoagu­lation? J. Am. Coll. Cardiol. 2015; 65 (23): 2494-95.

36. Панкратова Ю.В., Пигарова Е.А., Дзерано- ва Л.К. Витамин К-зависимые белки: остео­кальцин, матриксный Gla-белок и их внекост­ные эффекты. Ожирение и метаболизм. 2013; 2: 11-8 / Pankratova Yu.V., Pigarova E.A., Dzera- nova L.K. Vitamin K-dependent proteins: osteocal­cin, matrix Gla-protein and extra osseous effects. Ozhirenie i metabolizm. 2013; 2: 11-8 (in Russian).

37. Khor B., Van Cott E.M. Laboratory tests for protein C deficiency. Am. J. Hematol. 2010; 85 (6): 440-2.

38. Allison S.J. Activated protein C protective in IRI. Nat. Rev. Nephrol. 2015; 11 (8): 445.

39. Dong W, Wang H, Shahzad K., Bock F, Al- Dabet M.M., Ranjan S. et al. Activated protein C ameliorates renal ischemia-reperfusion injury by restricting Y-Box binding protein-1 ubiquitination. J. Am. Soc. Nephrol. 2015; 26 (11): 2789-99.

40. Bock F., Shahzad K., Wang H., Stoyanov S, Wolter J., Dong W. et al. Activated protein C ame­liorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc. Natl. Acad. Sci. USA. 2013; 110: 648-53.

41. Sidhu T.S., French S.L., Hamilton J.R. Differential signaling by protease-activated receptors: implica­tions for therapeutic targeting. Int. J. Mol. Sci. 2014; 15: 6169-83.

42. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M. et al. ARISTO­TLE Committees and Investigators. Apixaban ver­sus warfarin in patients with atrial fibrillation. N. Eng. J. Med. 2011; 365: 981-92.

43. Fox K.A., Piccini J.P., Wojdyla D., Becker R.C., Halperin J.L., Nessel C.C. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur. Heart J. 2011; 32: 2387-94.

44. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikel- boom J., Oldgren J., Parekh A. et al. Dabigatran ver­sus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-51.

45. Mega J.L., BraunwaldE, WiviottS.D., Bassand J.-P., Bhatt D.L., Bode C. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 2012; 366: 9-19.

Об авторах

Зыков Михаил Валерьевич, канд. мед. наук, науч. сотр., кардиолог.

Электронная подписка

Для получения доступа к тексту статей журнала воспользуйтесь услугой «Электронная подписка»:

Оформить подписку Подробнее об электронной подписке

Главный редактор

Лео Антонович Бокерия, академик РАН и РАМН

Лео Антонович Бокерия, доктор медицинских наук, профессор, академик РАН и РАМН, директор


 Если вы заметили опечатку, выделите текст и нажмите alt+A